Following a May 2013 research alliance between the companies focused on respiratory allergy therapies, immunotherapy specialist Stallergenes has partnered with DBV Technologies to develop and commercialise a treatment for birch pollen allergy using DBV’s Viaskin® epicutaneous drug delivery technology, which modulates the immune response to allergens. Stallergenes will fully fund DBV’s preclinical development programme, which aims to deliver a clinical candidate that uses Stallergenes’ birch pollen allergen, and in return will have global development and commercialisation rights to the product.